Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (MCK) delivers vital healthcare supply chain solutions through pharmaceutical distribution, medical-surgical product management, and technology services. This page provides investors and industry observers with direct access to McKesson's official news updates and market-moving developments.
Track earnings announcements, strategic partnerships, and regulatory filings alongside operational milestones shaping McKesson's role in healthcare logistics. Our curated feed consolidates press releases and verified news to help stakeholders monitor the company's performance in pharmaceutical wholesale and healthcare IT innovation.
Discover updates on McKesson's supply chain optimization initiatives, technology platform enhancements, and collaborations with hospitals, pharmacies, and manufacturers. Bookmark this page for efficient monitoring of developments impacting one of North America's leading healthcare distribution networks.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced progress on the opioid claims settlement involving U.S. states and territories. As of August 21, 2021, 42 states, 5 territories, and Washington, D.C. have joined the settlement, allowing the process to move forward. This next phase includes a 120-day period for political subdivisions to join, ending January 2, 2022. If enough subdivisions participate, the settlement will take effect 60 days after that. The companies aim to focus on secure medication delivery while providing relief to affected communities.
McKesson Corporation (NYSE:MCK) has announced an upcoming Investor Day scheduled for December 8, 2021, in New York City. Interested stakeholders can access a live audio webcast along with presentation slides via the company's Investor Relations website. McKesson is recognized as a global leader in healthcare supply chain management and has received accolades such as being named a Most Admired Company by FORTUNE and a Best Place to Work by the Human Rights Campaign Foundation.
McKesson Corporation (NYSE: MCK) announced its fiscal 2022 first-quarter financial results on August 4th. Investors can review the results on McKesson’s Investor Relations website. A live earnings conference call will be held today at 4:30 PM ET, with a replay available for twelve months. McKesson is recognized as a leader in healthcare supply chain management and has received accolades including 'Most Admired Company' in the healthcare wholesaler category by FORTUNE. Visit www.mckesson.com for more information.
The Board of Directors of McKesson Corporation (NYSE:MCK) declared a regular dividend of $0.47 per share on July 23, 2021, marking a 12% increase from the previous quarter's $0.42. This dividend will be payable on October 1, 2021 to stockholders on record as of September 1, 2021. McKesson is recognized as a leader in healthcare supply chain management and has received accolades such as being a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE.
McKesson Corporation (MCK) has announced an increase in its cash tender offer to purchase up to $922,154,000 of its outstanding Notes, up from the initial $500,000,000. This offer includes various series of Notes, with acceptance of all validly tendered and not withdrawn Notes prior to the Early Tender Time. The company expects to make payments on accepted Notes by July 23, 2021. The Offer will expire on August 4, 2021, unless extended. Barclays Capital Inc. and Citigroup Global Markets Inc. are leading the transaction.
McKesson Corporation (NYSE: MCK) announced early tender results for its cash tender offer to purchase up to $500 million of various Notes. As of July 21, 2021, the company intends to increase the Tender Cap to $922,154,000, after receiving $922,154,000 of validly tendered Notes. This includes Series like 6.00% Notes due 2041 and 4.883% Notes due 2044, with acceptance expected for 100% of valid tenders submitted by the Early Tender Time. The Offer expires on August 4, 2021, unless extended.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced a proposed settlement addressing the majority of opioid lawsuits from state and local entities. The settlement, contingent on participation from states and political subdivisions, could provide up to $21 billion over 18 years. Contributions include $6.4 billion from each AmerisourceBergen and Cardinal Health, and $7.9 billion from McKesson. The settlement is seen as a step towards resolving opioid claims, with strong legal defenses maintained in pending litigation if not finalized.
AmerisourceBergen, Cardinal Health, and McKesson have agreed to pay up to $1.179 billion to settle opioid-related claims with New York and its subdivisions, including Nassau and Suffolk Counties. This settlement is part of ongoing negotiations for a broader resolution concerning claims from various states. The distributors will receive claims dismissal in exchange for the settlement amount and associated legal fees. While disputing the allegations, the companies view this as a step toward focusing resources on safe medication delivery and supporting affected communities.
McKesson Corporation (NYSE: MCK) has initiated a cash tender offer to purchase up to $500 million of its outstanding debt securities, including 6.00% Notes due 2041 and other series. The offer will expire on August 4, 2021, with an early tender deadline set for July 21, 2021. Holders of the notes must tender their securities by this date to receive an additional early tender payment of $50 per $1,000 principal. Pricing is based on U.S. Treasury yields plus additional fixed spreads. The company may extend or terminate the offer under specific conditions.
McKesson Corporation (NYSE: MCK) has agreed to sell its European operations in six countries, including France and Italy, to the PHOENIX group. The divestiture includes McKesson's German headquarters and various subsidiaries but excludes remaining operations in the UK and other Northern European countries. This strategic move aims to streamline McKesson's focus on growth outside Europe. The transaction is set to close in 2022, pending regulatory approvals. McKesson will discuss this sale further during its earnings call on August 4, 2021.